Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Norway's Vistin Pharma Q3 profit falls

By Reuters News


Overview

  • Norway pharmaceutical firm's Q3 revenue was flat yr/yr as currency strength offset volume growth

  • Q3 EBITDA and net profit declined compared to last year

  • Company declared additional NOK 0.50/share cash dividend for Q4


Outlook

  • Company continues to focus on sales volume growth and onboarding new customer volume in 2026

  • Company to pay additional NOK 0.50 per share cash dividend in Q4 2026


Result Drivers

  • VOLUME GROWTH OFFSET BY CURRENCY - Co said higher sales volumes were offset by a stronger NOK against EUR, impacting revenue in local currency

  • NEW CUSTOMER VOLUME - Co said onboarding new customer volume helped increase sales volume and utilize manufacturing capacity


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

NOK 108.40 mln

Q3 Net Income

NOK 11 mln

Q3 EBITDA

NOK 19 mln


Reuters Recommended Reads

  • Oct 27 - Pharming Group Q3 revenue rises on US demand; tightens guidance

  • Oct 28 - GSK pipeline doubts, vaccine underperformance overshadow sales beat

  • Oct 28 - Generic drugmaker Sandoz cuts sales outlook, shares fall


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.